Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026
Eton Pharmaceuticals (ETON) had its price target raised by Craig Hallum from $29.00 to $30.00. They now have a "buy" rating on the stock.
Eton Pharmaceuticals (ETON) had its price target raised by HC Wainwright from $35.00 to $37.00. They now have a "buy" rating on the stock.
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution [Yahoo! Finance]
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution